Cue Biopharma (NASDAQ:CUE – Get Free Report)‘s stock had its “buy” rating restated by research analysts at B. Riley Financial in a research report issued on Wednesday, Benzinga reports.
Several other equities analysts also recently commented on CUE. Weiss Ratings downgraded Cue Biopharma from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, August 27th. Zacks Research raised Cue Biopharma to a “hold” rating in a research report on Monday, September 21st. Finally, Wall Street Zen downgraded Cue Biopharma from a “sell” rating to a “strong sell” rating in a research report on Saturday, September 26th. One equities research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $25.00.
Check Out Our Latest Research Report on CUE
Cue Biopharma Stock Performance
Cue Biopharma stock traded up $1.09 during mid-day trading on Wednesday, hitting $3.92. The company’s stock had a trading volume of 5,011,283 shares, compared to its average volume of 355,287. The company has a 50 day moving average of $23.13 and a 200-day moving average of $103.96. The stock has a market cap of $28.43 million, a PE ratio of -0.13 and a beta of 2.79. Cue Biopharma has a one year low of $2.83 and a one year high of $45.50.
Cue Biopharma (NASDAQ:CUE – Get Free Report) last announced its quarterly earnings data on Monday, November 16th. The company reported ($4.74) EPS for the quarter, missing the consensus estimate of ($2.24) by ($2.50). The business had revenue of $0.13 million during the quarter, compared to the consensus estimate of $1.03 million. Cue Biopharma had a negative net margin of 579.95% and a negative return on equity of 820.77%. On average, equities research analysts forecast that Cue Biopharma will post -21.79 EPS for the current fiscal year.
Insider Transactions at Cue Biopharma
In other news, CEO Shao-Lee Lin sold 11,087 shares of the stock in a transaction on Monday, October 12th. The stock was sold at an average price of $27.55, for a total transaction of $305,446.85. Following the transaction, the chief executive officer owned 694,908 shares of the company’s stock, valued at approximately $19,144,715.40. This represents a 1.57% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Sumita Ray sold 1,844 shares of the stock in a transaction on Monday, October 12th. The stock was sold at an average price of $28.05, for a total value of $51,724.20. Following the transaction, the insider directly owned 116,701 shares in the company, valued at $3,273,463.05. The trade was a 1.56% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last 90 days, insiders have sold 14,075 shares of company stock valued at $389,260. 14.56% of the stock is currently owned by corporate insiders.
Hedge Funds Weigh In On Cue Biopharma
Hedge funds and other institutional investors have recently made changes to their positions in the company. BlackRock Inc. purchased a new stake in shares of Cue Biopharma during the 2nd quarter worth $1,824,000. ADAR1 Capital Management LLC purchased a new stake in shares of Cue Biopharma during the 2nd quarter worth $1,742,000. Texas Capital Bank Wealth Management Services Inc purchased a new stake in shares of Cue Biopharma during the 2nd quarter worth $722,000. Seven Fleet Capital Management LP purchased a new stake in shares of Cue Biopharma during the 2nd quarter worth $338,000. Finally, Goldman Sachs Group Inc. purchased a new stake in shares of Cue Biopharma during the 3rd quarter worth $243,000. Institutional investors own 35.04% of the company’s stock.
Cue Biopharma Company Profile
Cue Biopharma, Inc. is a biotechnology company developing biologic medicines designed to selectively engage and modulate T cells. Its Immuno-STAT platform is intended to direct immune activity toward disease-specific targets, with potential applications in cancer and autoimmune disorders. The company’s research has included cancer candidates such as CUE-101, designed to target HPV16-positive cancers, and CUE-102, developed to target cancers expressing the WT1 protein. Cue Biopharma has also pursued programs intended to influence immune responses in autoimmune disease.
Read More
- Five stocks we like better than Cue Biopharma
- SpaceX’s Historic Starship Catch Raises a Bigger Question About Its AI Spending
- AMD Bets $8.2B on Physical AI: Could Robotics Be Its Next Growth Frontier?
- 3 Stocks Flashing Buy Signals With Historical Win Rates Above 85% After the Sell-Off
- Disney Has the Magic Touch: Dividend Growth and Buybacks Could Fuel a Breakout
Receive News & Ratings for Cue Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cue Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
